Global /Taiwan /Healthcare /Biotechnology /6550

Polaris Group

6550

• TWSE: 6550 • Delayed

17.50TWD -2.2%

0.5545 USD

As of 9 June 2026, Polaris Group has a market cap of $487.44M USD, ranking #15287 globally and #528 in Taiwan. It ranks #1361 in the Healthcare sector, and #261 in the Biotechnology industry.

Global Rank

15287

Country Rank

528

Sector Rank

1361

Industry Rank

261

Key Stats

Market Cap

$487.44MUSD

15.39B TWD

Enterprise Value

$504.08MUSD

15.91B TWD

Revenue (TTM)

$1.29MUSD

40.6M TWD

EBITDA (TTM)

-$83.91MUSD

-2.65B TWD

Net Income (TTM)

-$124.36MUSD

-3.93B TWD

PS Ratio

379.1

PB Ratio

2.9

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Shyan Chen open_in_new

Employees

165

Founded

2006

Website

polaris-group.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.2%	-1.1%	-11%	-44%	-51%	-44%	-54%	-82%	-75%

News

Markets

Exchange	Ticker	Price	Quotes
Taiwan Stock Exchange (TWSE) MIC: XTAI PRIMARY	6550 北極星藥業集團股份有限公司 ISIN: KYG7171A1085 Shares Out.: Shares Outstanding: 859.893M¹ Shares Float: 370.812M² TV: TradingView: TWSE: 6550 SA: Stock Analysis: TPE: 6550 YF: Yahoo Finance: 6550.TW GF: Google Finance: TPE: 6550 BA: Barron's: 6550 MS: Morningstar: XTAI: 6550	17.50 TWD	TV: TradingView: TWSE: 6550 SA: Stock Analysis: TPE: 6550 YF: Yahoo Finance: 6550.TW GF: Google Finance: TPE: 6550 BA: Barron's: 6550 MS: Morningstar: XTAI: 6550

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.47B 172.76B TWD 1K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 231%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 121%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$605.68M 19.13B TWD 24%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$601.09M 18.98B TWD 23%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$572.06M 18.06B TWD 17%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 37K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 33K%	19.0	United States
argenx SE EBR: ARGX	$47.69B 41.39B EUR 10K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$43.73B 68.19T KRW 9K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.5B 60.27B AUD 9K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.49B 33.71B CHF 9K%	37.2	Switzerland

chevron_leftBack